Accountable scientists. Excellent results. We know development™
We don't just talk about accountability — we build it into every program we run. Complex molecules, demanding timelines, high scientific stakes. Our experts have been here before. They know the way.
Our Mission
At Ardena, we are building the global leader in precision medicine development of new, innovative and complex molecules. Our mission is to enable current and next generation treatments get into the clinic and to patients faster. We pursue our mission by helping biopharma innovators navigate through the discovery and development process to create effective and compliant drugs for clinical trials.
Our Vision
To be the global leader in advanced drug development services, recognized for our scientific know-how, innovative technology platforms, and unwavering commitment to enabling current and next generation treatments get into the clinic and to patients faster.
We know development™. Let’s talk about yours.
Ardena is a CDMO and bioanalytical CRO built for the complexity of modern drug development. We specialize in drug product development, nanomedicine, and bioanalytical services and we work exclusively with the kind of molecules that keep other CDMOs up at night.
For biotech companies pushing the boundaries of what’s possible, we offer the scientific depth to match. Our drug product platform spans sterile and non-sterile dosage forms, spray drying, hot melt extrusion, and solid-state chemistry, a powerful toolkit for molecules with bioavailability challenges or demanding physicochemical profiles. We bring the same rigor to HPAPIs, controlled substances, and targeted therapies with complex linker, payload, or delivery requirements.
Our nanomedicine team specializes in the formulation and manufacturing of nanoparticle-based therapeutics. One of the most technically demanding areas in drug development and one where experience is everything.
Our bioanalytical scientists don’t just generate data. They help you understand your molecule, support your regulatory strategy, and keep your program moving.
With facilities across the US and Europe, we combine the responsiveness biotech teams need with the technical firepower their molecules demand.
Behind every complex molecule is a patient who needs it to work. That’s why we lead with CARE, being Communicative, Accountable, Reliable, and committed to Excellence. It’s how we run every program, every day. All in service of our mission: to accelerate the development of complex, innovative therapeutics and make precision medicine more accessible to the patients who are waiting for it.
Our Approach to Drug Development
Four principles that shape every program we run — from first formulation to final batch.
Integrated Service
Our drug product, nanomedicine, and bioanalytical capabilities are on one multidisciplinary platform. When the same team developing your nanoparticle formulation is talking directly to the scientists analyzing your bioanalytical data. One integrated program, built around your molecule, driven by experts who care from first formulation to clinical supply.
Agile Operations
Development plans change. That is the nature of the science. Our teams work with care on your program. We are always agile. When your program needs to pivot, we already have a plan. Fast, clear, honest communication at every step.
Phase-Appropriate Development
What your molecule needs at Phase I is not what it needs at Phase III. We calibrate our approach to match your stage, applying the right quality standards at the right time. Reliable from first formulation to final batch.
People First
Behind every program is an expert from our team. Our scientists, project managers, quality experts and regulatory experts know development. At Ardena, every role plays a vital part in the much bigger picture — our efforts contribute directly to a shared purpose: helping innovative therapies reach the patients who need them most.
Science with Responsibility
We develop medicines that improve lives. We take the same responsibility seriously when it comes to how we operate — for our people, our planet, and the partners who trust us.
Environment
We've committed to science-based emissions targets aligned with a 1.5°C pathway. That means real reductions in energy use and greenhouse gas emissions – not pledges. Renewable energy, circular waste practices, and water stewardship are built into how we run every facility.
Labor & Human Rights
700+ people across six facilities. Every one of them works in an environment built on CARE. We invest in the development of our scientists and operators because great programs are built by great people and great people stay where they're respected.
Ethics
Zero tolerance for bribery, corruption, and anti-competitive behaviour. We back that with a clear Code of Conduct, whistleblower protections, and data privacy standards that run from our Board to every supplier in our network. Accountability doesn't stop at our front door.
Sustainability Commitment
We report annually, set measurable targets, and hold ourselves accountable for the results. Sustainability isn't a communications exercise at Ardena. It's how we make decisions, choose suppliers, and run operations. The same care we apply to your molecule, we apply to our impact.
Leadership Team
Our leadership team brings decades of hands-on experience across drug development, formulation, manufacturing, bioanalysis, and global operations — so when your program hits a hard moment, there's someone in the room who has already solved it.
Chief Executive Officer
Jeremie joined Ardena as Chief Executive Officer in 2024. He brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience building and growing businesses globally, expending into new markets, and leading large-scale transformations in both publicly traded and privately held companies. Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO, and during his tenure there, led the successful acquisition and integration of multiple companies.
Chief Commercial Officer (CCO)
Henny Zijlstra joined Ardena as Chief Commercial Officer in May 2026. She is an accomplished commercial leader in the pharmaceutical and CDMO industry, with a career built on driving growth through strategic business development, brand positioning, and customer engagement.
Chief Financial Officer (CFO)
Ben Ash joined Ardena in 2026 as Chief Financial Officer. He brings more than 20 years of finance leadership experience, predominantly within the pharmaceutical sector.
Chief Scientific Officer
Since 2019, Ariane has overseen Ardena’s drug product activities, spearheading successful integration and transformation at Ardena Pamplona and expanding the company’s capabilities to include sterile services.
Global Head, CDMO
Ian joined Ardena in 2025 as US Managing Director. He has over 30 years of global experience across multiple functions in both the CDMO and Medical device industry. Ian spent 19 years of his career working at GE in Quality, Finance, Supply Chain, Technical services and Commercial operations. He then joined Catalent in 2013 where he was VP of Sales Operations and more recently GM for the Somerset site. He holds degree in Mechanical Engineering and an MBA from Northwestern University – Kellogg School of Management.
Global Head, CRO
Gunnar Flik joined Ardena in 2024 as Division Head of Bioanalytical Services. With over 20 years of experience in drug discovery within biotech and CRO environments, Gunnar brings a wealth of strategic vision and entrepreneurial expertise to his role. He is dedicated to developing comprehensive short- and long-term strategic plans aimed at optimizing efficiency, fostering growth, and enhancing profitability within Ardena’s Bioanalysis division.
Chief Quality Officer
Dipesh Patel joined Ardena in 2025 as Chief Quality Officer. He brings over 25 years of experience in the pharmaceutical industry, having held senior leadership roles across CDMOs, virtual biotech companies, and large-scale manufacturing organizations. With an academic background in Chemistry, Biology, and Toxicology, he has built a strong track record in both Quality and Operations, overseeing a broad range of dosage forms and regulatory frameworks.
Chief People Officer
Paul Edwards joined Ardena in 2026 as Chief People Officer, bringing over 30 years of international Human Resources leadership across complex, science-driven and global organisations. Paul has extensive experience in shaping people strategy to support organisational growth and transformation, most recently serving in senior HR leadership roles at Catalent Pharma Solutions.
Chief Information Officer
Peter Rose joined Ardena in 2025 as Chief Information Officer. He brings over 25 years of Information Technology leadership experience spanning multiple industries, including chemicals and pharmaceuticals. Most recently, he was the global head of IT infrastructure and security at Diversey, a global chemical manufacturer, driving technology-enabled transformation, and leading a successful IT migration of the company into the Solenis Group.
Our journey is your molecule's advantage.
Every site added, every capability acquired, every team grown has made Ardena more expert at the one thing that matters – developing complex molecules with the accountability, reliability, and excellence that patients deserve. We know development. This timeline shows how we earned the right to say it.
Ardena acquires Catalent site in New Jersey
Ardena acquires a state-of-the-art drug product manufacturing facility in Somerset, New Jersey, establishing its first US site and opening the door to North American bioanalytical services.
Ardena acquires Idifarma
Ardena acquires Idifarma in Pamplona, Spain, adding highly potent compound manufacturing, spray drying, and oral solid dosage expertise.
GHO Capital becomes the new reference shareholder
GHO Capital acquires Ardena from Mentha Capital, partnering with management to strengthen the service platform and expand internationally.
Ardena acquires ChemConnection
Ardena acquires Chemconnection, adding drug substance and nanomedicine expertise at the Pivot Park life sciences campus in Oss, Netherlands.
Launch of the Ardena brand
Ardena launches as a unified brand, combining the capabilities of PharmaVize and Crystallics under one identity and one mission.
Ardena acquires ABL
Ardena acquires ABL, broadening the platform to include bioanalytical and drug discovery services for preclinical and clinical programs.
Acquisition of Crystallics
Ardena acquires Crystallics, adding pioneering solid-state research and proprietary solid form screening technology based in the Netherlands.
Mentha Capital invests in Pharmavize
Mentha Capital invests in PharmaVize and the M&A strategy begins. The vision: build a fully integrated CDMO for complex molecules.
Ardena earns its first GMP licence
Ardena earns its first GMP licence — Hivenyl oral solution for Barrier Therapeutics, New Jersey. The proof of concept that clinical-grade development was the right focus.
PharmaVize is founded
PharmaVize is founded in Mariakerke, Belgium — a CDMO built around drug product development, analytical services, and GMP production. The scientific foundation that everything Ardena would become was built on.
